Research programme: mTOR/PI3K inhibitors - Roche

Drug Profile

Research programme: mTOR/PI3K inhibitors - Roche

Alternative Names: PI-103

Latest Information Update: 09 Sep 2013

Price : $50

At a glance

  • Originator The Institute of Cancer Research
  • Class Pyrimidines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Sep 2013 Preclinical development is ongoing in United Kingdom
  • 21 Apr 2009 Preclinical pharmacodynamics data in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 26 Apr 2004 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top